Osteoporosis: what is important for a primary care doctor to know?


DOI: https://dx.doi.org/10.18565/therapy.2022.2.77-85

Toroptsova N.V., Nikitinskaya O.A., Dobrovolskaya O.V.

V.A. Nasonova Research Institute of Rheumatology, Moscow
Abstract. Osteoporosis occupies one of the leading places in morbidity structure of people over 50 years of age, and its social significance is associated with its main complications – low-energy fractures of the vertebral bodies and peripheral skeleton bones, treatment of which leads to high financial costs in healthcare. Article considers the modern criteria for diagnosing osteoporosis, presents a mandatory and additional laboratory examination of the patient to exclude other possible causes of bone mineral density decrease, as well as recommendations for choosing an antiosteoporotic medicine depending on the clinical picture of the disease and the risk of fractures. Recommendations concerning the duration of therapy depending on the used medicament and its efficacy, as well as indications for resuming treatment after a previous withdrawal are given.
Keywords: diagnosis of osteoporosis, low-energy fracture, fracture risk, treatment of osteoporosis, osteoporosis
Read entire article

Literature


  1. Лесняк О.М., Баранова И.А., Белова К.Ю. с соавт. Остеопороз в Российской Федерации: эпидемиология, медико-социальные и экономические аспекты проблемы (обзор литературы). Травматология и ортопедия России. 2018; 1: 155–168. doi: 10.21823/2311-2905-2018-24-1-155-168. [Lesnyak O.M., Baranova I.A., Belova K.Yu. et al. Osteoporosis in Russian Federation: epidemiology, socio-medical and economical aspects (Review). Travmatologiya i ortopediya Rossii = Traumatology and Orthopedics of Russia. 2018; 1: 155–168 (in Russ.)]. https://dx.doi.org/10.21823/2311-2905-2018-24-1-155-168.

  2. Добровольская О.В., Торопцова Н.В., Лесняк О.М. Экономические аспекты осложненного остеопороза: стоимость лечения в течение первого года после перелома. Современная ревматология. 2016; 3: 29–34. [Dobrovolskaya O.V., Toroptsova N.V., Lesnyak O.M. Economic aspects of complicated osteoporosis: The cost of treatment in the first year after fracture. Sovrermennaya revmatologiya = Modern Rheumatology Journal. 2016; 3: 29–34 (In Russ.)]. https://dx.doi.org/10.14412/1996-7012-2016-3-29-34.

  3. Аудит состояния проблемы остеопороза – 2020. Доступ: https://osteoporosis-russia.ru/audit-sostoyaniya-problemy-osteoporoza-2020 (дата обращения – 11.02.2022). [Audit of the state of the problem of osteoporosis 2020. URL: https://osteoporosis-russia.ru/audit-sostoyaniya-problemy-osteoporoza-2020 (date of access – 11.02.2022).

  4. Добровольская О.В., Торопцова Н.В. Постменопаузальный остеопороз: качество жизни пациенток после переломов. Эффективная фармакотерапия. 2015; 46: 8–13. [Dobrovolskaya O.V., Toroptsova N.V. Postmenopausal osteoporosis: post-fracture quality of female patients’ life. Effektivnaya farmakoterapiya = Effective Pharmacotherapy. 2015; 46: 8–13 (In Russ)].

  5. Белая Ж.Е., Белова К.Ю., Бирюкова Е.В. с соавт. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Остеопороз и остеопатии. 2021; 2: 4–47. [Belaya Z.E., Belova K. Yu., Biryukova E.V. et al. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporoz i osteopatii = Osteoporosis and Bone Diseases. 2021; 2: 4–47 (In Russ.)]. https://dx.doi.org/10.14341/osteo12930.

  6. Siminoski K., Jiang G., Adachi J.D. et al. Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures. Osteoporos Int. 2005; 16(4): 403–10. https://dx.doi.org/10.1007/s00198-004-1709-z.

  7. Остеопороз: руководство для врачей. Под ред. О.М. Лесняк. М.: ГЭОТАР-Медиа. 2016; 464 с. [Osteoporosis: a guide for physicians. Ed. by Lesnyak O.M. Moscow: GEOTAR-Media. 2016; 464 pp. (In Russ.)]. ISBN: 978-5-9704-3986-9.

  8. Lindsay R., Silverman S.L., Cooper C. et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001; 285(3): 320–23. https://dx.doi.org/10.1001/jama.285.3.320.

  9. Gehlbach S., Saag K.G., Adachi J.D. et al. Previous fractures at multiple sites increase the risk for subsequent fractures: The global longitudinal study of osteoporosis in women. J Bone Miner Res. 2012; 27(3): 645–53. https://dx.doi.org/10.1002/jbmr.1476.

  10. Dede A.D., Tournis S., Dontas I., Trovas G. Type 2 diabetes mellitus and fracture risk. Metabolism. 2014; 63(12): 1480–90. https://dx.doi.org/10.1016/j.metabol.2014.09.002

  11. National Osteoporosis Foundation (NOF) and International Society for Clinical Densitometry (ISCD). Recommendations to DXA Manufacturers for FRAX® Implementation Guide. URL: http://www.nof.org/files/nof/public/content/resource/862/files/392.pdf (date of access – 11.02.2022).

  12. Bauer D.C., Black D.M., Bouxsein M.L. et al. Foundation for the National Institutes of Health (FNIH) Bone Quality Project. Treatment-related changes in bone turnover and fracture risk reduction in clinical trials of anti-resorptive drugs: A meta-regression. J Bone Miner Res. 2018; 33(4): 634–42. https://dx.doi.org/10.1002/jbmr.3355.

  13. Diez-Perez A., Adachi J.D., Agnusdei D. et al. IOF CSA Inadequate Responders Working Group. Treatment failure in osteoporosis. Osteoporos Int. 2012; 23(12): 2769–74. https://dx.doi.org/10.1007/s00198-012-2093-8.

  14. Bauer D., Garnero P., Hochberg M. et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: The fracture intervention trial. J Bone Miner Res. 2005; 21(2): 292–99. https://dx.doi.org/10.1359/jbmr.051018.

  15. Yamamoto T., Tsujimoto M., Hamaya E., Sowa H. Assessing the effect of baseline status of serum bone turnover markers and vitamin D levels on efficacy of teriparatide 20 mg/day administered subcutaneously in Japanese patients with osteoporosis. J Bone Miner Metab. 2013; 31(2): 199–205. https://dx.doi.org/10.1007/s00774-012-0403-z.

  16. International Society for Clinical Densitometry. 2013 ISCD official positions – adult. URL: http://www.altecmedico.com/wp-content/uploads/2016/02/2013-ISCD-Official-Positions-%E2%80%93-Adult.pdf (date of access – 11.02.2022).

  17. Pepe J., Body J.J., Hadji P. et al. Osteoporosis in premenopausal women: A clinical narrative review by the ECTS and the IOF. J Clin Endocrinol Metab. 2020; 105(8): dgaa306. https://dx.doi.org/10.1210/clinem/dgaa306.

  18. Rozenberg S., Bruyere O., Bergmann P. et al. How to manage osteoporosis before the age of 50. Maturitas. 2020; 138: 14–25. https://dx.doi.org/10.1016/j.maturitas.2020.05.004.

  19. Lyles K.W., Colon-Emeric C.S., Magaziner J.S. et al. HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357(18): 1799–809. https://dx.doi.org/10.1056/NEJMoa074941.

  20. Мазуров В.И., Лесняк О.М., Белова К.Ю. с соавт. Алгоритмы выбора терапии остеопороза при оказании первичной медико-санитарной помощи и организации льготного лекарственного обеспечения отдельных категорий граждан, имеющих право на получение государственной социальной помощи. Системный обзор и резолюция экспертного совета российской ассоциации по остеопорозу. Профилактическая медицина. 2019; 1: 57–65. [Mazurov V.I., Lesnyak O.M., Belova K.Yu. et al. Algorithm for selection of drug for osteoporosis treatment in primary care and in organization of provision with medicinal products of citizens eligible for state social assistance. Review of the literature and position of Russian Association on Osteoporosis Expert Council. Profilakticheskaya medicina = The Russian Journal of Preventive Medicine. 2019; 1: 57–65 (In Russ.)]. https://dx.doi.org/10.17116/profmed20192201157.

  21. Adler R., El-Hajj Fuleihan G., Bauer D. et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016; 31(1): 16–35. https://dx.doi.org/10.1002/jbmr.2708.

  22. Белая Ж.Е., Bilezikian J.P., Ершова О.Б. с соавт. Возможности длительной терапии постменопаузального остеопороза: обзор результатов клинических исследований деносумаба и резолюция совета экспертов российской ассоциации по остеопорозу (РАОП). Остеопороз и остеопатии. 2018; 1: 17–22. [Belaya Z.E., Bilezikian J.P., Ershova O.B. et al. Long-term treatment options for postmenopausal osteoporosis: results of recent clinical studies of Denosumab. Osteoporoz i osteopatii = Osteoporosis and Bone Diseases. 2018; 1: 17–22 (In Russ.)]. https://dx.doi.org/10.14341/osteo9760.

  23. Gallagher J., Genant H., Crans G. et al. Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab. 2005; 90(3): 1583–87. https://dx.doi.org/10.1210/jc.2004-0826.

  24. Orwoll E., Scheele W., Paul S. et al. The effect of teriparatide [Human Parathyroid Hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003; 18(1): 9–17. https://dx.doi.org/10.1359/jbmr.2003.18.1.9.

  25. Saag K., Shane E., Boonen S. et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357(20): 2028–39. https://dx.doi.org/10.1056/NEJMoa071408.

  26. European Medicines Agency: Protelos/Osseor (strontium ranelate) to remain available but with further restrictions 15 April 2014 EMA 235924/2014. J Rheumatol. 2005; 32: 1556–62.

  27. Richy F., Dukas L., Schacht E. Differential effects of D-hormone analogs and native vitamin D on the risk of falls: a comparative meta-analysis. Calcif Tissue Int. 2008; 82(2): 102–7. https://dx.doi.org/10.1007/s00223-008-9102-0.

  28. Bone H.G., Wagman R.B., Brandi M.L. et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017; 5(7): 513–23. https://dx.doi.org/10.1016/S2213-8587(17)30138-9.

  29. Silverman S.L., Kupperman E.S., Bukata S.V. et al. Fracture healing: A consensus report from the International Osteoporosis Foundation Fracture Working Group. Osteoporos Int. 2016; 27(7): 2197–206. https://dx.doi.org/10.1007/s00198-016-3513-y.

  30. Malouf-Sierra J., Tarantino U., Garcia-Hernandez P.A. et al. Effect of teriparatide or risedronate in elderly patients with a recent pertrochanteric hip fracture: Final results of a 78-week randomized clinical trial. J Bone Miner Res. 2017; 32(5): 1040–51. https://dx.doi.org/10.1002/jbmr.3067.


About the Autors

Natalya V. Toroptsova, MD, head of the Laboratory of osteoporosis, V.A. Nasonova Research Institute of Rheumatology. Address: 115522, Moscow, 34A Kashirskoe Highway. E-mail: torop@irramn.ru.
ORCID: https://orcid.org/0000-0003-4739-4302
Oksana A. Nikitinskaya, PhD, senior researcher of the Laboratory of osteoporosis, V.A. Nasonova Research Institute of Rheumatology. Address: 115522, Moscow, 34A Kashirskoe Highway. E-mail: nikitinskaya@niir.su.
ORCID: https://orcid.org/0000-0001-6759-8367
Olga V. Dobrovolskaya, PhD, researcher of the Laboratory of osteoporosis, V.A. Nasonova Research Institute of Rheumatology. Address: 115522, Moscow, 34A Kashirskoe Highway. E-mail: epid@irramn.ru.
ORCID: https://orcid.org/0000-0002-2809-0197


Similar Articles

Back to Content

Бионика Медиа